TICKERNERD
Menu
FDMTFDMTHealthcare · Biotechnology

FDMT Stock Forecast: 4D Molecular Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$13
+0.87% on the day

The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. hold a median 12-month price target of $28 — +120.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$693.9M
Ticker Nerd rank
56 / 100
Median analyst target
$28
Analysts covering
12
Revenue$3.8M+25106.7% y/y
Operating income−$77.0M
Net income−$72.9M
Free cash flow−$70.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.2%
1M
−13.2%
YTD
+69.3%
1Y
+31.5%
From 52W high
−24.2%
From 52W low
+76.6%
$7
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

FDMT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 4D Molecular Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
56 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
93
Accruals
68
Growth
61
Value
58
Revisions
54
Size
48
Volatility
47
Quality
44
Issuance
12

Momentum (93): The shares have been drifting up relative to others.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

FDMT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FDMT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26FDMTHigh $37Median $28Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $18Median $28High $37

The green dot is the last close — the median target sits +120.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Oct 2026Chardan CapitalMaintainsBuy$26 → $25
29 Sept 2026B of A SecuritiesMaintainsBuy$29 → $33
14 Sept 2026Cantor FitzgeraldUpgradeOverweight—
14 Sept 2026Cantor FitzgeraldUpgradeOverweight$20
31 July 2026B. Riley SecuritiesInitiatesBuy—
31 July 2026B. Riley SecuritiesInitiatesBuy$37
20 July 2026HC Wainwright & Co.ReiteratesBuy—
20 July 2026HC Wainwright & Co.ReiteratesBuy$36
30 Mar 2026JefferiesAssumesBuy$40 → $21
20 Mar 2026HC Wainwright & Co.ReiteratesBuy—
19 Mar 2026Chardan CapitalMaintainsBuy—
19 Mar 2026RBC CapitalMaintainsOutperform—
28 Jan 2026BarclaysInitiatesOverweight—
18 Dec 2025Chardan CapitalMaintainsBuy—
11 Nov 2025BarclaysMaintainsOverweight—
11 Nov 2025Chardan CapitalMaintainsBuy—
11 Nov 2025RBC CapitalMaintainsOutperform—
21 Oct 2025RBC CapitalReiteratesOutperform—
12 Aug 2025Chardan CapitalMaintainsBuy—
12 Aug 2025Roth CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FDMT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

FDMT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, 4D Molecular Therapeutics, Inc. returned +31.5% against +16.2% for the S&P 500, dividends included.

FDMT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26FDMTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FDMT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

4D Molecular Therapeutics, Inc. (FDMT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.2×

Cheaper than 90% of US stocks

Price / sales
7.7×

Cheaper than 17% of US stocks

Price / book
1.7×

Cheaper than 49% of US stocks

EV / EBITDA
−2.0×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
25106.7%

Higher than 99% of US stocks

Earnings growth (YoY)
25106.7%

Higher than 99% of US stocks

Gross margin
—
Operating margin
−2037.2%

Higher than 4% of US stocks

Net margin
−194.7%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−43.3%

Higher than 23% of US stocks

Return on assets
−25.1%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

4D Molecular Therapeutics, Inc. (FDMT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • 4D Molecular Therapeutics, Inc. has a market value of $693.9M and an enterprise value of $371.8M.

  • Revenue in the twelve months to 30 June 2026: $92.0M. The latest quarter grew 25106.7% year on year.

  • Net income over the same four quarters: −$179.2M, a −194.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$156.0M.

  • Shares outstanding: 55.2M.

  • Trailing P/E: −5.2×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • 4D Molecular Therapeutics, Inc. employs 196 people — $469K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

FDMT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FDMT4D Molecular Therapeutics, Inc.$693.9M
56
AVTXAvalo Therapeutics, Inc.$706.0M
36
CADLCandel Therapeutics, Inc.$707.6M
41
DSGNDesign Therapeutics, Inc.$708.6M
61
VSTMVerastem, Inc.$712.3M
59
SLDBSolid Biosciences, Inc.$717.0M
44
MDXGMiMedx Group, Inc.$686.4M
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 4D Molecular Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest FDMT news & analysis

4DMT to Host Investor Day on October 21, 2026

GlobeNewsWire · 5 Oct 2026neutral

4D Molecular Therapeutics announced it will host an Investor Day on October 21, 2026, where the company will share insights on the advancing clinical profile and commercial vision for 4D-150. Renowned retinal experts, including Dr. Arshad M. Khanani and Dr. Carl C., will participate.

Why it matters — FDMT watchers would care because the investor day offers a scheduled opportunity to hear the company's latest perspective on the clinical progress and commercial plans for its key candidate 4D-150.

4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway

Seeking Alpha · 29 Sept 2026positive

4D Molecular Therapeutics remains rated 'Buy' as its gene therapy 4D-150 advances, with pivotal phase 3 trials for wet AMD (4FRONT-1 and 4FRONT-2) underway and topline data expected in 2027. Phase 3 studies for diabetic macular edema have also begun.

Why it matters — FDMT watchers will care because clinical data indicate 4D-150 could significantly reduce injection burden in wet AMD and DME, potentially making it a major player in the large anti-VEGF market.

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

GlobeNewsWire · 28 Sept 2026positive

4D Molecular Therapeutics announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME), marking the therapy's advancement into Phase 3 for a second large market retina indication. The company also reported two-year data from its SPECTRA clinical trial.

Why it matters — FDMT watchers would care because 4D-150 is moving into a second large-market retina indication with a Phase 3 trial now underway, potentially expanding the therapy's commercial opportunity beyond its first indication.

4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 17 Sept 2026neutral

4D Molecular Therapeutics, Inc. presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. No specific details from the presentation were disclosed in this item.

Why it matters — A watcher of FDMT would care because presentations at major healthcare conferences offer opportunities for company updates and visibility among investors.

FAQ

Frequently asked questions about FDMT stock

What is the FDMT stock price forecast for 2026-2027?

The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FDMT stock a buy right now?

Of the 12 analysts covering 4D Molecular Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 4D Molecular Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FDMT?

As at 8 Oct 2026, 4D Molecular Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).

Will FDMT stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +120.5% from the last close, and Ticker Nerd's factor model ranks 4D Molecular Therapeutics, Inc. 56 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FDMT stock forecast for 2030?

No analyst covering 4D Molecular Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FDMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $37 over the next 12 months.

How has FDMT stock performed over the past year?

4D Molecular Therapeutics, Inc. returned +31.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does 4D Molecular Therapeutics, Inc. do?

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform.

What is the latest news on FDMT?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "4DMT to Host Investor Day on October 21, 2026". 4D Molecular Therapeutics announced it will host an Investor Day on October 21, 2026, where the company will share insights on the advancing clinical profile and commercial vision for 4D-150. Renowned retinal experts, including Dr. Arshad M. Khanani and Dr. Carl C., will participate.

Company

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision. Its current clinical development programs are concentrated in retina and pulmonology, reflecting a portfolio aimed at treating serious conditions through targeted gene delivery. In ophthalmology, the company is advancing therapies for retinal vascular diseases and other eye disorders, while its respiratory work includes programs for lung-directed treatment of genetic disease. 4D Molecular Therapeutics, Inc. plays a specialized role in the gene therapy market by combining vector engineering, tissue targeting, and disease-focused development to support next-generation genetic medicine candidates.

CEO Dr. David H. Kirn M.D. · 196 employees · United States · https://www.4dmoleculartherapeutics.com